Establishment of personalized treatment for BIM deletion polymorphism-positive lung cancer using circulating tumor cells

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K08189
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53030:Respiratory medicine-related
• Research Institution: Toho University
• Principal Investigator: Isobe Kazutoshi 東邦大学, 医学部, 准教授 (70385607)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: EGFR遺伝子変異陽性非小細胞肺癌 / オシメルチニブ / BIM-γ / 循環腫瘍細胞

Outline of Final Research Achievements

A prospective study was conducted to clarify the relationship between the response rate of osimertinib in EGFR mutation-positive non-small cell lung cancer and the mRNA expression level of BIM-γ in circulating tumor cells. Circulating tumor cells were harvested using the ClearCell FX system and subjected to quantitative real-time PCR. The response rate of osimertinib was lower in the BIM-γ high expression group (n = 15) than in the BIM-γ low expression group (n = 15) (26% vs. 73.3%, p = 0.011). It was suggested that overexpression of BIM-γ mRNA in circulating tumor cells of patients with EGFR mutation-positive non-small cell lung cancer could be a poor prognostic factor for osimertinib.

Free Research Field

呼吸器内科

Academic Significance and Societal Importance of the Research Achievements

本研究は血液検体を用いた確実なサンプリングに基づいた個別化治療のシステム構築を目的にしており、得られた結果はBIM-γのmRNAの発現量を層別化因子とした原発性肺癌の個別化治療法の確立に大きく貢献するもので、本研究は非常に特色のある研究であると同時にその社会的意義も大きい。